Skip to main content

Table 3 Univariate and multivariate logistic regression analyses for acute severe lymphopenia

From: Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era

  Univariate HR (95% CI) P Multivariate HR (95% CI) P
Patient-related factor
 Age (per 1 year) 1.02 (1.00–1.03) 0.098   
 Sex (Male vs. Female) 0.30 (0.18–0.47) <.001 0.33 (0.19–0.55) <.001
 KPS
  (80 vs. ≤70) 0.90 (0.53–1.56) 0.716   
  (≥90 vs. ≤70) 0.54 (0.30–0.97) 0.038   
 Baseline TLC (< 1000/μL vs. ≥1000/μL) 1.83 (1.09–3.07) 0.021 1.69 (0.94–3.03) 0.082
Tumor-related factor
 Extent of resection
  (Subtotal/Partial vs. Total) 2.85 (1.75–4.64) <.001 2.40 (1.40–4.11) 0.001
  (Biopsy vs. Total) 1.57 (0.62–3.94) 0.338 2.43 (0.84–6.98) 0.100
IDH1 mutation
  (Yes vs. No) 0.64 (0.21–2.01) 0.447 0.75 (0.22–2.57) 0.649
  (Unknown vs. No) 2.68 (1.56–4.64) <.001 1.83 (0.93–3.62) 0.079
 MGMT (Methylated vs. Unmethylated) 0.69 (0.43–1.11) 0.122   
 Subventriclular zone (Involved vs. Uninvolved) 1.27 (0.80–2.00) 0.308   
Treatment-related factor
 The cumulative dose of temozolomide (per 100 mg/m2) 0.98 (0.97–1.00) 0.087 0.99 (0.97–1.02) 0.530
 PTV1 volume (per 10 cm3) 1.02 (1.00–1.03) 0.012 1.02 (1.00–1.03) 0.042
 PTV2 volume (per 10 cm3) 1.02 (1.00–1.05) 0.083   
 Radiotherapy modality (IMRT vs. 3D-CRT) 0.32 (0.19–0.51) <.001 0.48 (0.27–0.87) 0.015
 Total dose (per 1 Gy) 0.95 (0.89–1.01) 0.072   
 No. of fractionation (per 1) 0.99 (0.90–1.08) 0.749   
  1. Abbreviations: 3D-CRT three-dimensional conformal radiotherapy, CI confidence interval, HR hazard ratio, IMRT intensity-modulated radiotherapy, KPS Karnofsky performance status, PTV planning target volume, TLC total lymphocyte count